Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 48, Issue 5, 2003, Pages 1398-1407

  De Benedetti, Fabrizio ^a   Meazza, Cristina ^b   Vivarelli, Marina ^b   Rossi, Federica ^c   Pistorio, Angela ^c   Lamb, Rebecca ^d   Lunt, Mark ^d   Thomson, Wendy ^d   Abinun, M ^e   Becker, M ^e   Bell, A ^e   Craft, A ^e   Crawley, E ^e   David, J ^e   Foster, H ^e   Gardener Medwin, J ^e   Griffin, J ^e   Hall, A ^e   Hall, M ^e   Herrick, A ^e   Hollingworth, P ^e   Holt, L ^e   Jones, S ^e   Pountain, G ^e   Ryder, C ^e   Southwood, T ^e   Stewart, I ^e   Venning, H ^e   Wedderburn, L ^e   Woo, P ^e   Wyatt, S ^e   Ravelli, Angelo ^c   Donn, Rachelle ^d   Martini, Alberto ^c   more..

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e IRCCS Osp Pediatrico Bambino Gesu ^*

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; MACROPHAGE MIGRATION INHIBITION FACTOR; TRIAMCINOLONE ACETONIDE;

ALLELE; ARTICLE; BLOOD LEVEL; CAPILLARY ELECTROPHORESIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ITALY; JOINT MOBILITY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVIAL FLUID LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; INFANT; MACROPHAGE MIGRATION-INHIBITORY FACTORS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; TREATMENT OUTCOME;

EID: 0038708312     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10882     Document Type: Article

References (35)

1. Svantesson H, Akesson A, Eberhardt K, Elborg R. Prognosis in juvenile rheumatoid arthritis with systemic onset: a follow-up study. Scand J Rheumatol 1983;12:139-44.
2. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991;17:892-901.
3. Calabro JJ, Holgerson WB, Sonpal GM, Khoury MI. Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin Arthritis Rheum 1976;5:257-98.
4. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43:2402-9.
5. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
6. De Benedetti F, Pignatti P, Massa M, Corti A, Cassani G, Martini A. Tumor necrosis factor (TNF)-α and soluble TNF receptors in systemic juvenile rheumatoid arthritis. Br J Rheumatol 1997;36:581-8.
7. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease? J Rheumatol 1998;25:203-7.
8. Meazza C, Travaglino P, Pignatti P, Magni-Manzoni S, Ravelli A, Martini A, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:232-7.
9. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 1996;93:7849-54.
10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71.
11. Santos L, Hall P, Metz C, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 2001;123:309-14.
12. Donn RP, Shelley E, Ollier WER, Thomson W, the British Paediatric Rheumatology Study Group. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782-5.
13. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
14. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986;29:274-81.
15. Ruperto N, Ravelli A, Pistorio A, Malattia C, Viola S, Cavuto S, et al. The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19 Suppl 23:S91-5.
16. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2402-9.
17. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002;3:170-6.
18. Donn RP, Zeggini E, Lamb R, Shelley E, Ollier WER, British Paediatric Rheumatology Study Group, et al. Linkage and association of macrophage migration inhibitory factor (MIF) with juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S580.
19. Barton A, Salway F, Thomson W, Silman A, Ollier W, Worthington J, et al. MIF polymorphism is associated with susceptibility to inflammatory arthritis [abstract]. Rheumatology (Oxford) 2002;41 Suppl 1:126.
20. Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29;1671-3.
21. De Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2:1061-6.
22. Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, et al. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci 1999;40:247-50.
23. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-8.
24. Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 2002;13 Suppl 1:S7-13.
25. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000;179(S 1-2):127-31.
26. Desaymard C, Kaplan C, Fournier C, Manigne P, Hayem F, Kahn MF, et al. Major histocompatibility complex markers and disease heterogeneity in one hundred eight patients with systemic onset juvenile chronic arthritis. Rev Rhum Engl Ed 1996;63:9-16.
27. Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFα gene and HLA genes. Arthritis Rheum 1999;42:2577-82.
28. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
29. Ravelli A, Ramenghi B, Di Fuccia G, Ruperto N, Zonta L, Martini A. Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatr 1994;83:428-32.
30. Cassidy JT, Petty RE, Sullivan DB. Abnormalities in the distribution of serum immunoglobulin concentrations in juvenile rheumatoid arthritis. J Clin Invest 1973;52:1931-6.
31. Schneider R, Lang BA, Reilly BJ, Laxer RM, Silverman ED, Ibanez D, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992;120:200-5.
32. Leech M, Metz C, Santos L, Peng T, Holdsworth SR, Bucala R, et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998;41:910-7.
33. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997;158:5514-7.
34. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-70.
35. Senter PD, Al-Abed Y, Metz CN, Benigni F, Mitchell RA, Chesney J, et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A 2002;99:144-9.